Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned a consensus rating of “Moderate Buy” from the seventeen analysts that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $55.38.

Several analysts have commented on KYMR shares. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Morgan Stanley lifted their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Stephens started coverage on shares of Kymera Therapeutics in a research note on Monday, November 18th. They set an “overweight” rating and a $65.00 price objective for the company. Guggenheim lifted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, BTIG Research initiated coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective for the company.

Kymera Therapeutics Trading Up 1.7 %

NASDAQ:KYMR opened at $41.59 on Friday. The company has a market cap of $2.69 billion, a PE ratio of -17.77 and a beta of 2.16. Kymera Therapeutics has a twelve month low of $22.35 and a twelve month high of $53.27. The company’s 50 day moving average is $44.67 and its two-hundred day moving average is $43.73.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same period in the previous year, the business posted ($0.90) EPS. The business’s quarterly revenue was down 20.9% compared to the same quarter last year. As a group, analysts expect that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently made changes to their positions in the company. FMR LLC increased its position in shares of Kymera Therapeutics by 5.8% during the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after purchasing an additional 282,301 shares in the last quarter. Wellington Management Group LLP boosted its stake in Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after purchasing an additional 308,954 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Kymera Therapeutics by 85.8% during the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after buying an additional 368,394 shares in the last quarter. Eventide Asset Management LLC raised its position in shares of Kymera Therapeutics by 9.9% in the third quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock valued at $24,039,000 after buying an additional 45,803 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Kymera Therapeutics by 11.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after buying an additional 47,507 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.